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Background: Hypertension (HT) is rarely reported in patients affected by Neuroblastoma (NB), and management
guidelines are lacking. Clinical features andperioperativemedical treatment in suchpatientswere reviewed to1) as-
certain whether a shared treatment strategy exists among centers and 2) if possible, propose some recommenda-
tions for the perioperative management of HT in NB patients.
Methods:A retrospectivemulticenter surveywas conducted on patients affected byNBwhopresentedHT symptoms.
Results: From 2006 to 2014, 1126 children were registered in the Italian Registry of Neuroblastoma (RINB). Of these, 21
withHT (1.8%)were included in our analysis. Pre- and intraoperativeHTmanagementwas somewhat dissimilar among
the participating centers, apart from a certain consistency in the intraoperative use of the alpha-1 blocker urapidil. Six of
the 21 patients (28%) needed persistent antihypertensive treatment at a median follow-up of 36 months (range 4–
96 months) despite tumor removal. Involvement of the renal pedicle was the only risk factor constantly associated to
HT persistency following surgery. A correlation between the presence of HT and the secretion of speciﬁc catecholamines
and/or compression of the renal vascular pedicle could not be demonstrated.INB, Italian Registry of Neuroblastoma; GICOP, Italian Group of Pediatric Surgical Oncologists; IDRFs, image-deﬁned risk factors;
ational Neuroblastoma Staging System; INRGSS, International Neuroblastoma Risk Group Staging System; CT, computerized to-
lylmandelic acid; HVA, homovanillic acid.
to Giannina Gaslini, Largo G. Gaslini 5, 16147, Genoa, Italy. Tel.: +39 010 56362217; fax: +39 010 3075092.
1634 L. Pio et al. / Journal of Pediatric Surgery 52 (2017) 1633–1636Conclusion: Based on this retrospective review of NB patients with HT, no deﬁnite therapeutic protocol can be recom-
mended owing to heterogeneity of adopted treatments in different centers. A proposal of perioperativeHTmanagement
in NB patients is however presented.
Level of evidence: IV.
© 2017 Elsevier Inc. All rights reserved.Neuroblastoma (NB) is one of the most frequent pediatric solid
tumors. It often originates from the adrenal gland or from the adjacent
paravertebral sympathetic ganglia and frequently involves the kidney.
Hypertension (HT) is a relatively rare symptom of NB, its reported
incidence ranging between 10% and 19% of cases. Few studies have fo-
cused on the perioperative management of HT, and most of these
have been case reports [1–9]. Both cardiac and neurological complica-
tions of HT have been described [10].
Both catecholamine secretion and renal vascular compression have
been advocated as the possible pathophysiological mechanism of HT in
NB [2,3]. Although the secretion of catecholamines may be increased in
NB patients, HT and other symptoms of catecholamine excess frequently
observed in pheochromocytoma have been reported in relatively few
childrenwith NB (1–9). This difference is probably owing to the presence
of many storage granules in pheochromocytoma, which release large
quantities of catecholamines, thereby causing HT. In neuroblastic cells,
this storagemechanismseems to be inefﬁcient, causing intracellular gran-
ule disruption, the inactivation of catecholamines and the release of their
metabolites into the circulation. A small number of NB do display abun-
dant storage granules and patients can exhibit blood pressure patterns
like those of patients with pheochromocytoma [11–14]. Chemotherapy
may result in additional catecholamine release and HT owing to tumor
lysis, thus warranting close observation during preoperative cycles [4].
Renal artery stenosis is a possible cause of HT and has been observed
in about 3% to 10% of cases of pediatric HT [15,16]. NB causing renovascu-
lar HT owing to extrinsic aortic narrowing and/or stenosis of the renal ar-
tery has been reported [2,5].
Preoperative echocardiography is the cornerstone in the diagnostic
workup of these patients, as catecholamine excess can induce several
complications other than, or subsequent to, HT, including seizures and
heart failure, cardiomyopathy, cardiomegaly and cardiogenic shock
[3,6,15,17–26]. All in all, preoperative HT control has lowered reported
mortality from 13% to 45% to 0%–3% in patients with catecholamine-
secreting tumors [27].
The anesthesiological intraoperativemanagement of hyper- and hypo-
tensive peaks has rarely been reported [3,4]. Whatever the cause of HT in
NB, symptoms are generally well controlled by the preoperative adminis-
tration of alpha-1 adrenergic blocking agents, such as phenoxybenzamine,
phentolamine, prazosin and, more recently, doxazosin [3,4,6,9,17–26].
Despite effective preoperative alpha-1adrenergic blockade, intraop-
erative HT may still occur, especially when the tumor is being manipu-
lated. Therefore, the availability of a wide range of rapidly acting
medications to treat intraoperative hypertensive peaks is mandatory;
these include prostaglandin E1, diuretics, calcium channel antagonists,
sodium nitroprusside, hydralazine, magnesium sulfate, phentolamine,
adenosine, and fenoldopam [4,6,20–22]. Beta blockers, such as propran-
olol, labetalol, atenolol and esmolol, may be administered intraopera-
tively in association with alpha-1 blockers to control catecholamine-
induced arrhythmia and tachycardia [4,6]. Postresection hypotension
may be successfully managed bymeans of continuous iv administration
of dopamine in the ﬁrst 24 postoperative hours [6].
In the present study, we retrospectively reviewed an Italian series of
NB patients with HT, with a view to assessing the possible correlation be-
tween HT and the secretion of speciﬁc catecholamines and/or compres-
sion of the renal vascular pedicle. We also evaluated the perioperative
management of HT to ﬁnd out whether a possible treatment recommen-
dation can be presented.1. Materials and methods
The Italian Registry of Neuroblastoma (RINB) collects all newly diag-
nosed cases of NB in Italy, together with demographic, chemotherapy,
surgical, and follow-up data.
The Italian Group of Pediatric Surgical Oncologists (GICOP) conduct-
ed a retrospective survey of all the patients affected by NB with associ-
ated HT registered in the RINB from 2006 to 2014. HT was deﬁned as
blood pressure values higher than the 99th percentile + 5 mmHg, as
stated by the National High Blood Pressure Education ProgramWorking
Group in 2004 [28]. All children who had undergone surgical resection
were included in the present study.
The following data were retrospectively collected in an electronic
database: series demographics, diagnostic workup, including assays of
urinary and/or blood catecholamines, image-deﬁned risk factors
(IDRFs) present on preoperative imaging (CT or MRI), tumor histology
according to the International Neuroblastoma Pathology Classiﬁcation
(INPC) [29], tumor staging according to the International Neuroblasto-
ma Staging System (INSS) [30] and the International Neuroblastoma
Risk Group Staging System (INRGSS) [31], and biomolecular features
such as the presence or absence of MYCN ampliﬁcation.
Pre-, peri- and postoperative antihypertensive treatment regimens
were examined. Treatment duration, drugs administered and possible
HT persistence during follow-up were recorded.
Anesthesiological treatments were collected and divided into
premedication, epidural, induction, muscle relaxation, maintenance
and the need for packed red blood cell transfusion.
Surgery was deﬁned as complete if more than 95% of the tumor had
been resected (microscopic residual disease), as leaving minimal resid-
ual disease (if more than 90% but less than 95% of the tumor had been
removed, macroscopic minimal residual disease), or as incomplete (if
less than 90% of the tumor had been removed).
Clinical follow-up examination was conducted by a pediatric ne-
phrologist, an oncologist and a cardiologist, and included 24-h continu-
ous blood pressure measurement and radiological reevaluation (CT,
MRI and ultrasonography scan).2. Results
From 2006 to 2014, 1126 children affected by NB were registered in
the RINB, 25 ofwhompresentedHT (2.2%). Four of these 25 children did
not undergo surgical resection, and were therefore excluded from the
analysis. Consequently, the study cohort comprised 21 patients. Pa-
tients' demographics and tumor characteristics are detailed in Table 1.
Vanillylmandelic acid (VMA) and homovanillic acid (HVA) were
tested in all patients and were found elevated in 9 (43%).Norepineph-
rine and epinephrine were assayed in only 3 patients, and proved to
be elevated in all of them. Dopamine was never analyzed.
An age-comparable series of 28 patients presenting with non-HT NB
and involvement of the renal vascular pedicle was examined to detect
any signiﬁcant differences. The only ﬁnding that emerged from this
analysis was that a relatively higher proportion of patients in the
nonhypertensive group displayed increased VMA/HVA (89% of
normal-tension NB patients vs 43% of HT NB patients). No statistical
analysis was conducted on these data.
Table 1
Clinical characteristics of the study patients (N = 21).
Clinical characteristics N./Total %
Gender:
• Male 11 52.3%
• Female 10 47.6%
Age at surgery (months), median (range) 15
(1 month–18 years)
Stage INSS (INRGSS)
• 1 (L1) 5 23.8%
• 3 (L2) 9 42.9%
• 4 (M) 7 33.3%
Renal pedicle involvement (IDRF) 8 38%
Histology:
• Schwannian stoma poor Neuroblastoma 20 95.2%
• Ganglioneuroblastoma Intermixed 1 4.8%
MYCN status:
• Ampliﬁed 1 4.8%
• Not Ampliﬁed 20 95.2%
Vanillylmandelic acid (VMA) and homovanillic acid (HVA)
• Normal values 11 57%
• Elevated values 9 43%
Preoperative chemotherapy 12 57.1%
Preoperative antihypertensive treatment 18 85.7%
Preoperative antihypertensive treatment duration (days),
median (range)
90 (5–300)
Persistent postoperative HT 6 28.6%
Surgical resection:
• Complete 15 71.4%
• Minimal Residual 2 9.6%
• Incomplete 4 19%
Follow-up (median 36 months, range 4–96 months):
• Complete remission 12 57.1%
• Residual disease 6 28.6%
• Progression of disease/death 3 14.3%
Table 2
Characteristics of the antihypertensive treatment in 21 patients.
Hypertensive treatment N
patients
%
patients
Preoperative 18 85.7
Single-drug treatment ACE inhibitors (captopril) 3
Calcium antagonist (amlodipine) 3
Beta blockers (atenolol) 2
Multiple-drug
treatment
(2–4 drugs)
1. Beta blockers (atenolol) 10
+ Calcium antagonists
(nifedipine)
9
+ Alpha blockers (doxazosin) 5
+ ACE inhibitors (captopril) 4
+ Diuretics (furosemide) 3
Intraoperative 6 28.6
Single-drug treatment Alpha Blockers (urapidil) 5
Double-drug treatment 1. Diuretics (furosemide) 1
2. Calcium antagonists (nifedipine) 1
Postoperative 6 28.6
Single-drug treatment Calcium antagonists (nifedipine) 2
Double-drug treatment 1. Calcium antagonists (nifedipine) 4
2. Beta Blockers (atenolol) 4
1635L. Pio et al. / Journal of Pediatric Surgery 52 (2017) 1633–1636Preoperative radiological imaging showednormal-sized kidneys (age-
and sex-matched) in all patients. Involvement of the renal vascular pedi-
cle was observed in 8 of the 21 patients (38%) in our study cohort (Fig. 1).
The four excluded patients had not undergone surgery owing to the
persistence of 3 or more IDRFs after chemotherapy (Patient 1: bilateral
renal pedicle, aorta, celiac artery, superior mesenteric artery; Patient 2:
renal pedicle, hepatic pedicle, cava, aorta; Patient 3: renal pedicle, supe-
rior mesenteric artery, aorta; Patient 4: renal pedicle, cava, aorta). Only
Patient 4 had increased VMA/HVA. Patients 1 and 2 are alive with active
disease and are on dual anti-HT therapy. Patients 3 and 4 have died.
None of the patients presented with cardiac hypertensive-related
complications on preoperative echocardiography.
Preoperative antihypertensive treatment was necessary in 18 pa-
tients (86%) for a median preoperative time of 90 days (range:
5–300 days). This consisted of single-drug therapy in 8 patients and
multiple-drug therapy in 10 patients (Table 2).Fig. 1. Computerized tomography (axial section): encasement of renal pedicles.The induction and maintenance of anesthesia were almost uniform
in all centers, withmidazolam being used in 19 patients (90%), propofol
for the induction phase in 17 (81%), rocuronium formuscle relaxation in
18 (86%) and sevorane for anesthesia maintenance in all patients. Epi-
dural anesthesia was performed in 9 patients (43%). Six patients devel-
oped intraoperative hypertensive peaks, which were successfully
managerwith alpha 1 blockers (urapidil) in 5 cases andwith a combina-
tion of calcium antagonist (nifedipine) plus diuretic (furosemide) in the
remaining case.
No hypertensive complications were documented during surgical
procedures.
Surgical results are detailed in Table 1. None of the patients in this
series underwent nephrectomy to achieve complete resection.
On follow-up examination conducted after a median of 36 months
(range 4–96 months), 12 patients were in complete remission (57%),
6 presentedwith residual disease (28%) and 3 had died owing to disease
progression (14%). Six patients (28%) presented persistent postopera-
tive HT despite complete tumor resection in 4 of them and minimal re-
sidual in 1. Long-term antihypertensive treatmentwas therefore started
in these patients. Four of these six patients had been treated with anti-
hypertensive medications for more than 100 days preoperatively.
Six out of 8 childrenwith documented involvement of the renal ped-
icle (on IDRF evaluation) presented persistence of HT after surgery. As
these 6 patients constituted the whole cohort of children with persis-
tent postoperative HT, renal pedicle involvement seems to be the only
risk factor predictive of persistent HT (owing to the small number, no
statistical analysis was conducted on these data). These patients
underwent a thorough postoperative radiological assessment by
means of US-Doppler and CT scan to detect possible renal
hypotrophy/atrophy possibly owing to persistent spasm of the renal ar-
tery owing to prolonged intraoperative vessel manipulation and/or im-
paired renal perfusion observed during surgery. This analysis revealed
no pathological ﬁndings in patients with persistent HT, showing
normal-shaped and normal-sized kidneys in all of them, regardless of
the involvement of the renal pedicle.3. Discussion
NB is one of the most common solid tumors in infancy, accounting
for approximately 8%of childhood cancers. HTwasdocumented in near-
ly 2.2% of the cases recorded in the RINB, thus constituting a rare condi-
tion associated to NB; its management varies widely according to the
center involved.
To the best of our knowledge, the present study analyzed the largest
series of children affected by NBwith HT. Nevertheless, it is still limited,
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diagnostic and therapeutic protocols within the different centers in-
volved in the study. Unfortunately, only urinary metabolites of vasoac-
tive amines, namely VMA and HVA, were routinely investigated in all
patients, and few centers performed detailed assays of dopamine, epi-
nephrine and norepinephrine.
Surprisingly, only 1 patient from our series showedMYC-N ampliﬁca-
tion.We could notﬁnd any clinical explanation for such an unusual distri-
bution (considering that at least 16 patients had stage L2/M disease).
Although noneof thepatients fromour series presentedwith cardiac
hypertensive-related complications, a complete cardiologic assessment,
including echocardiography, is mandatory in the correct preoperative
workup of these patients [3,6,11,25,26].
With regard to the antihypertensive medications used in our series,
the wide heterogeneity in drug selection, both preoperatively and
perioperatively, is immediately evident. This is mainly owing to the
lack of a recognized and accepted guideline dedicated to cases of NB
presenting with HT. However, a certain consistency was observed re-
garding the use of one rapidly acting alpha-1 blocker, namely urapidil,
which proved to be quite effective in themanagement of intraoperative
hypertensive peaks. Although described in the intraoperative manage-
ment of pheochromocytoma in adult patients [23], to the best of our
knowledge, urapidil administration has never been reported in children
affected by NB presenting with HT.
In this retrospective study, preoperative anti-HT therapywasnot ho-
mogeneous: 18/21 underwent preoperative anti-HT therapy; the re-
maining three patients were stage L1 on diagnosis and did not receive
any anti-HT therapy. The three centers concerned were therefore
contacted; it transpired that preoperative treatment had not been un-
dertaken owing to the short time (b7 days) between the diagnosis of
hypertension and surgical intervention. In all 18 patients, preoperative
anti-HT therapy achieved HT control without any clinical complication.
One patient underwent prolonged treatment (300 days) owing to the
‘unresectable’ nature of the tumor (stage L2 withmultiple IDRFs). The pa-
tientwas eventually transferred to another center andunderwent surgery.
As reported by Avanzini and colleagues [32], IDRFs remain unchanged in
50% of cases after chemotherapy, and this can delay surgical resection.
Nearly 30% (6/21) of the patients in our series showed persistently
increased blood pressure levels following medical and surgical treat-
ment. Of note, in only 1 of these 6 patients might this condition have
been explained by persistent disease owing to incomplete surgery. We
could not ﬁnd any plausible reason for HT persistence in the remaining
5 patients, since all of them underwent thorough postoperative radio-
logical assessment by means of US-Doppler and CT scan, without any
renal hypotrophy/atrophy being documented. Similarly, the persistence
of HT despite surgical treatment was documented in 1 out of 12 cases
reported by Madre et al. [1], without any evident clinical reason.
Involvement of the renal pedicle, as detected on preoperative radio-
logical assessment (IDRFs), seems to be the only risk factor that strongly
predicts the postoperative persistence of HT; this scenariowas observed
in 75% of patients with renal pedicle involvement, who constituted the
whole cohort of children with persistent postoperative HT.
On the basis of this retrospective review of NB patients with HT, no
deﬁnite therapeutic protocol can be recommended. However, we
would highlight a certain agreement on the intraoperative use of an
alpha-1 adrenergic blocker (namely urapidil) in association with a
beta-adrenergic blocker and a calcium channel antagonist to control
tachycardia and possible arrhythmias. An effective combination of
these proposedmedicationsmay limit the risk of cardiac complications,
which may affect anesthetic and surgical outcomes.
Similarly, postresection hypotension and hypovolemia should be
carefully addressed by means of continuous infusion of dopamine and
ﬂuid replacement, preferably in a pediatric intensive care setting, at
least for the ﬁrst 24 h postoperatively.
This study was presented at the 48th Congress of the International
Society of Pediatric Oncology (SIOP).Acknowledgment
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